✦ LIBER ✦

Quality of Life After Sipuleucel-T Therapy: Results From a Randomized, Double-blind Study in Patients With Androgen-dependent Prostate Cancer

✍ Scribed by Beer, Tomasz M.; Schellhammer, Paul F.; Corman, John M.; Glodé, L. Michael; Hall, Simon J.; Whitmore, James B.; Frohlich, Mark W.; Penson, David F.

Book ID: 123149428
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 685 KB
Volume: 82
Category: Article
ISSN: 0090-4295
DOI: 10.1016/j.urology.2013.04.049

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Integrated Safety Data From 4 Randomized

Integrated Safety Data From 4 Randomized, Double-Blind, Controlled Trials of Autologous Cellular Immunotherapy With Sipuleucel-T in Patients With Prostate Cancer

✍ Hall, Simon J.; Klotz, Laurence; Pantuck, Allan J.; George, Daniel J.; Whitmore, 📂 Article 📅 2011 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 85 KB

Evaluation of quality of life in patient

Evaluation of quality of life in patients with previously untreated advanced prostate cancer receiving maximum androgen blockade therapy or LHRHa monotherapy: a multicenter, randomized, double-blind, comparative study

✍ Yoichi Arai; Hideyuki Akaza; Takashi Deguchi; Masato Fujisawa; Mikio Hayashi; Yo 📂 Article 📅 2008 🏛 Springer-Verlag 🌐 English ⚖ 258 KB

Integrated data from 2 randomized, doubl

Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer

✍ Celestia S. Higano; Paul F. Schellhammer; Eric J. Small; Patrick A. Burch; John 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 402 KB

## Abstract ## BACKGROUND: Sipuleucel‐T is an investigational active cellular immunotherapy product designed to stimulate an immune response against prostate cancer. The safety and efficacy of sipuleucel‐T was evaluated in 2 identically designed, randomized, double‐blind, placebo‐controlled trials

Quality of Life in Patients with Testost

Quality of Life in Patients with Testosterone Recovery after Long Term Androgen Deprivation Therapy for High Risk Prostate Cancer

✍ Nabid, A.; Carrier, N.; Martin, A.; Bahary, J.; Souhami, L.; Duclos, M.; Vincent 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 78 KB

980 A randomized phase 2 study evaluatin

980 A randomized phase 2 study evaluating the optimal sequencing of sipuleucel-T and androgen deprivation therapy (ADT) in biochemically-recurrent prostate cancer (BRPC): Immune results with a focus on humoral responses

✍ Antonarakis, E.S.; Kibel, A.S.; Adams, G.W.; Karsh, L.I.; Elfiky, A.; Shore, N.D 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 202 KB

Intermittent chemotherapy in patients wi

Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer : Results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel

✍ Tomasz M. Beer; Christopher W. Ryan; Peter M. Venner; Daniel P. Petrylak; Gurkam 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 109 KB 👁 2 views

## Abstract ## BACKGROUND. Survival in patients with metastatic, chemotherapy‐naive, androgen‐independent prostate cancer (AIPC) is improved with 10 to 12 cycles of docetaxel‐containing chemotherapy but further management is undefined. In the current study, the authors examined retreatment with th